ArticleBMC infectious diseases2025
Comparative analysis of Chlamydia pneumoniae pneumonia (CPP) and Mycoplasma pneumoniae pneumonia in children and risk factors of severe CPP.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Predictive Model for Critical Illness Infection in Hospitalized Children with RSV Infection: A Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Risk factors for severeFrontiers in pediatrics · 2026Article
- Clinical characteristics of Chlamydia pneumoniae pneumonia in 145 children: a single-centre retrospective study.Frontiers in pediatrics · 2026Article
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Machine learning-based identification of inflammatory biomarkers for predicting pulmonary consolidation in children with Chlamydia pneumoniae infection.Frontiers in pediatrics · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundChlamydia penumoniae (CP) pneumonia (CPP) in children often receives less clinical attention due to its relatively mild presentation. This study comparatively analyzed CPP and Mycoplasma pneumoniae pneumonia (MPP), and investigated risk factors for severe CPP.
methodsA retrospective analysis was conducted on 176 CPP patients and 176 concurrently hospitalized MPP patients during the same period to compare clinical features. CPP cases were further stratified into severe and mild subgroup to identify risk factors.
resultsThe number of hospitalized children with CPP increased in 2024 compared to 2023, with a significant surge observed from December 2024 to February 2025. CPP patients were significantly older than MPP patients (mean age: 10.53 ± 2.89 vs. 6.68 ± 2.88, p < 0.05) and exhibited longer durations of cough and higher rates of chest pain (p < 0.05). Laboratory findings revealed significantly elevated white blood cell (WBC) and eosinophil (EOS) counts in CPP versus MPP (p < 0.05). Severe CPP accounted for 6.8% of cases, and binary logistic regression identified eosinophil count as a potential biomarker for severe CPP (p < 0.05).
conclusionsThe number of hospitalized children with CPP increased in 2024 compared to 2023. CPP manifested more prominent cough and chest pain symptoms compared to MPP patients. EOS count levels may serve as a potential biomarker of severe CPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.